The path to appropriate biosimilar management by Jim Rebello May 10, 2021Biosimilar, Biosimilar Management, Biosimilars, FDA, Magellan Health, Magellan Healthcare, Magellan RX, Magellan Rx Management, Medical Benefit, Oncology Biosimilars, Specialty Pharmacy
Trends in Oncology: A Focus on Medical Pharmacy Spend by Magellan Rx Management October 26, 2020Biosimilars, Magellan Health, Magellan RX, Magellan Rx Management, Medical Pharmacy, Medical Pharmacy Spend, Medical Pharmacy Trend Report, Oncology, Oncology Biosimilars, Oncology Spend, Pharmacy Trends, Specialty Spend
The Future is Now: The 17th Annual Specialty Summit by Magellan Rx Management September 11, 2020Biosimilars, COVID-19, Future of Genomics, Future of Specialty Pharmacy, Magellan, Magellan Health, Magellan RX, Magellan Rx Management, Magellan Rx Management Specialty Summit, MRx Specialty Summit, Oncology Biosimilars, Precision Medicine in Oncology, specialty drugs
Top 10 Takeaways: 2019 Medical Pharmacy Trend Report by Kristen Reimers April 21, 2020Billion Dollar Drugs, Biosimilars, Magellan, Magellan Health, Magellan RX, Magellan Rx Management, Medical Pharmacy, Medical Pharmacy Management, Medical Pharmacy Trend Report, Oncology Biosimilars, Specialty Clinical Solutions, Specialty Medications
3 Key Trends to Consider for Oncology Management by Rebecca Borgert June 5, 2019Cancer, Cancer treatment, FDA, Magellan, Magellan Health, Magellan Healthcare, Magellan RX, Magellan Rx Management, Medical Benefit Drug Management, Medical Oncology Spend, Novel Cancer Drugs, Oncology, Oncology Biosimilars, Oncology Management
